Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter SchmidJavier CortesLajos PusztaiHeather McArthurSherko KümmelJonas BerghCarsten DenkertYeon Hee ParkRina HuiNadia HarbeckMasato TakahashiTheodoros FoukakisPeter A FaschingFatima CardosoMichael UntchLiyi JiaVassiliki KarantzaJing ZhaoGursel AktanRebecca DentJoyce O'Shaughnessynull nullPublished in: The New England journal of medicine (2020)
Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).